Hybrid-drug design targeting pseudomonas aeruginosa DHPS and DHFR

In this study, we successfully present the dual-target design hypothesis to inhibit both dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) enzymes using a novel scheme that integrates our previous antibiotic-phytochemical interaction data, fragment combination and knowledge-based me...

Full description

Saved in:
Bibliographic Details
Main Authors: Jayaraman, Premkumar, Daniel, Lim Chu Siang, Siddiqi, Mohammad Imran, Dhillon, Sarinder Kaur, Sakharkar, Kishore R., Sakharkar, Meena K.
Other Authors: BioMedical Engineering Research Centre
Format: Article
Language:English
Published: 2014
Subjects:
Online Access:https://hdl.handle.net/10356/84863
http://hdl.handle.net/10220/24068
https://www.bioscience.org/2013/v5e/af/666/fulltext.htm
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
Description
Summary:In this study, we successfully present the dual-target design hypothesis to inhibit both dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) enzymes using a novel scheme that integrates our previous antibiotic-phytochemical interaction data, fragment combination and knowledge-based methods. Both the enzymes are well established antibacterial targets from folate biosynthesis pathway and their synergistic modulation by a single hybrid entity may have profound therapeutic benefits. Evaluation of the designed hybrid compounds based on their physico-chemical properties has indicated them as promising drug candidates with drug-like pharmacotherapeutic profiles. In addition, the stereo-electronic properties such as HOMO, LUMO and MEP maps calculated by quantum chemical methods gave a good correlation with the common pharmacophoric features required for dual-site interactions. Furthermore, docking and dynamics simulation studies reveal that the designed hybrid compounds have favorable binding affinity and stability in both pterin-binding site of DHPS and folate-binding site of DHFR by forming strong hydrogen bonds and hydrophobic interactions with key active-site residues. Looking forward this study could serve as a prospective lead in the process of new natural-product based hybrid-drugs development.